Drug Delivery to the Central Nervous System

Overview

Journal Nat Rev Mater

Date 2024 Mar 11

PMID 38464996

Authors

Elizabeth Nance

Suzie H Pun

Rajiv Saigal

Drew L Sellers

Affiliations

Soon will be listed here.

Abstract

Despite the rising global incidence of central nervous system (CNS) disorders, CNS drug development remains challenging, with high costs, long pathways to clinical use and high failure rates. The CNS is highly protected by physiological barriers, in particular, the blood-brain barrier and the blood-cerebrospinal fluid barrier, which limit access of most drugs. Biomaterials can be designed to bypass or traverse these barriers, enabling the controlled delivery of drugs into the CNS. In this Review, we first examine the effects of normal and diseased CNS physiology on drug delivery to the brain and spinal cord. We then discuss CNS drug delivery designs and materials that are administered systemically, directly to the CNS, intranasally or peripherally through intramuscular injections. Finally, we highlight important challenges and opportunities for materials design for drug delivery to the CNS and the anticipated clinical impact of CNS drug delivery.

Citing Articles

The neuroimmune nexus: unraveling the role of the mtDNA-cGAS-STING signal pathway in Alzheimer's disease.

Quan S, Fu X, Cai H, Ren Z, Xu Y, Jia L Mol Neurodegener. 2025; 20(1):25.

PMID: 40038765 PMC: 11877805. DOI: 10.1186/s13024-025-00815-2.

Biology, Pathology, and Targeted Therapy of Exosomal Cargoes in Parkinson's Disease: Advances and Challenges.

Almasi F, Abbasloo F, Soltani N, Dehbozorgi M, Moghadam Fard A, Kiani A Mol Neurobiol. 2025; .

PMID: 39998798 DOI: 10.1007/s12035-025-04788-7.

Metal nanoparticles in neuroinflammation: impact on microglial dynamics and CNS function.

Alaei M, Koushki K, Taebi K, Yousefi Taba M, Keshavarz Hedayati S, Shahbaz S RSC Adv. 2025; 15(7):5426-5451.

PMID: 39967886 PMC: 11833603. DOI: 10.1039/d4ra07798a.

Blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system.

Wang C, Xue Y, Markovic T, Li H, Wang S, Zhong Y Nat Mater. 2025; .

PMID: 39962245 DOI: 10.1038/s41563-024-02114-5.

Pooled screening for CAR function identifies novel IL-13Rα2-targeted CARs for treatment of glioblastoma.

Gordon K, Perez C, Garmilla A, Lam M, Aw J, Datta A J Immunother Cancer. 2025; 13(2).

PMID: 39933837 PMC: 11815465. DOI: 10.1136/jitc-2024-009574.

References

Carpentier A, Canney M, Vignot A, Reina V, Beccaria K, Horodyckid C . Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med. 2016; 8(343):343re2. DOI: 10.1126/scitranslmed.aaf6086. View

Chu C, Jablonska A, Lesniak W, Thomas A, Lan X, Linville R . Optimization of osmotic blood-brain barrier opening to enable intravital microscopy studies on drug delivery in mouse cortex. J Control Release. 2019; 317:312-321. DOI: 10.1016/j.jconrel.2019.11.019. View

Marcos-Contreras O, Brenner J, Kiseleva R, Zuluaga-Ramirez V, Greineder C, Villa C . Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain. J Control Release. 2019; 301:54-61. PMC: 6510023. DOI: 10.1016/j.jconrel.2019.03.008. View

Stewart G, Taylor M, Johnson R, Chellman G . Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor. Exp Neurol. 1997; 145(1):24-37. DOI: 10.1006/exnr.1997.6448. View

Vanlandewijck M, He L, Mae M, Andrae J, Ando K, Del Gaudio F . A molecular atlas of cell types and zonation in the brain vasculature. Nature. 2018; 554(7693):475-480. DOI: 10.1038/nature25739. View

Sampath P, Amundson E, Wall M, Tyler B, Wani M, Alderson L . Camptothecin analogs in malignant gliomas: comparative analysis and characterization. J Neurosurg. 2003; 98(3):570-7. DOI: 10.3171/jns.2003.98.3.0570. View

Couch J, Yu Y, Zhang Y, Tarrant J, Fuji R, Meilandt W . Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med. 2013; 5(183):183ra57, 1-12. DOI: 10.1126/scitranslmed.3005338. View

Marcos-Contreras O, Greineder C, Kiseleva R, Parhiz H, Walsh L, Zuluaga-Ramirez V . Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier. Proc Natl Acad Sci U S A. 2020; 117(7):3405-3414. PMC: 7035611. DOI: 10.1073/pnas.1912012117. View

Card J, Rinaman L, Schwaber J, Miselis R, Whealy M, Robbins A . Neurotropic properties of pseudorabies virus: uptake and transneuronal passage in the rat central nervous system. J Neurosci. 1990; 10(6):1974-94. PMC: 6570305. View

10.

Montagne A, Barnes S, Sweeney M, Halliday M, Sagare A, Zhao Z . Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015; 85(2):296-302. PMC: 4350773. DOI: 10.1016/j.neuron.2014.12.032. View

11.

Saver J, Goyal M, Bonafe A, Diener H, Levy E, Pereira V . Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015; 372(24):2285-95. DOI: 10.1056/NEJMoa1415061. View

12.

Chu D, Sellers D, Bocek M, Fischedick A, Horner P, Pun S . MMP9-sensitive polymers mediate environmentally-responsive bivalirudin release and thrombin inhibition. Biomater Sci. 2015; 3(1):41-5. PMC: 4289632. DOI: 10.1039/C4BM00259H. View

13.

Szentistvanyi I, PATLAK C, Ellis R, Cserr H . Drainage of interstitial fluid from different regions of rat brain. Am J Physiol. 1984; 246(6 Pt 2):F835-44. DOI: 10.1152/ajprenal.1984.246.6.F835. View

14.

Nduom E, Yang C, Merrill M, Zhuang Z, Lonser R . Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms. J Neurosurg. 2013; 119(2):427-33. PMC: 4746720. DOI: 10.3171/2013.3.JNS122226. View

15.

Winkler E, Sengillo J, Sagare A, Zhao Z, Ma Q, Zuniga E . Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci U S A. 2014; 111(11):E1035-42. PMC: 3964055. DOI: 10.1073/pnas.1401595111. View

16.

Furtado D, Bjornmalm M, Ayton S, Bush A, Kempe K, Caruso F . Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. Adv Mater. 2018; 30(46):e1801362. DOI: 10.1002/adma.201801362. View

17.

Householder K, Dharmaraj S, Sandberg D, Wechsler-Reya R, Sirianni R . Fate of nanoparticles in the central nervous system after intrathecal injection in healthy mice. Sci Rep. 2019; 9(1):12587. PMC: 6715675. DOI: 10.1038/s41598-019-49028-w. View

18.

Oldendorf W . Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am J Physiol. 1971; 221(6):1629-39. DOI: 10.1152/ajplegacy.1971.221.6.1629. View

19.

Johnsen K, Burkhart A, Thomsen L, Andresen T, Moos T . Targeting the transferrin receptor for brain drug delivery. Prog Neurobiol. 2019; 181:101665. DOI: 10.1016/j.pneurobio.2019.101665. View

20.

Thorne R, Frey 2nd W . Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet. 2001; 40(12):907-46. DOI: 10.2165/00003088-200140120-00003. View